Search Results - "Welch, Mary Roberta"

Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM) by Goldlust, Samuel Aaron, Chang, Jong Hee, Narita, Yoshitaka, Welch, Mary Roberta, Green, Richard M., Drappatz, Jan, Piccioni, David Eric, Kim, Yu Jung, Melear, Jason M., Tanaka, Shota, Wei, Kuo-Chen, Fink, Karen L., Pitz, Marshall W., Cloughesy, Timothy Francis, de Groot, John Frederick, McClellan, Nanci, Hitron, Matthew, Xu, Bo, Jin, Bo, Lebedinsky, Claudia

“…2022 Background: ODE is an investigational cancer vaccine derived from Wilms tumor 1. WIZARD was a randomized, adaptive, phase 3 study to test ODE + bev vs bev…”
Get full text

Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization by Lee, Eudocia Quant, Trippa, Lorenzo, Fell, Geoffrey, Rahman, Rifaquat, Arrillaga-Romany, Isabel, Drappatz, Jan, Welch, Mary Roberta, Galanis, Evanthia, Ahluwalia, Manmeet Singh, Colman, Howard, Nabors, Louis B., Hepel, Jaroslaw T., Schiff, David, Kaley, Thomas Joseph, Lu-Emerson, Christine, Chiocca, E. Antonio, Reardon, David A., Ligon, Keith L., Alexander, Brian Michael, Wen, Patrick Y.

“…2012 Background: Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial is a phase II platform trial using response adaptive…”
Get full text

Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma by Reardon, David A., Brem, Steven, Desai, Arati Suvas, Bagley, Stephen Joseph, Kurz, Sylvia Christine, De La Fuente, Macarena Ines, Nagpal, Seema, Welch, Mary Roberta, Hormigo, Adilia, Forsyth, Peter A. J., Mandel, Jacob Joseph, Khagi, Simon, Aiken, Robert, Walbert, Tobias, Lieberman, Frank S., Portnow, Jana, Battiste, James, Gillespie, Elisabeth, Lowy, Israel, Skolnik, Jeffrey

“…2004 Background: Novel T cell-enabling therapies plus checkpoint inhibition may improve OS in GBM. INO-5401 (synthetic DNA plasmid encoding hTERT, WT-1, PSMA)…”
Get full text

Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or other therapies by Donovan, Laura, Gedailovich, Samuel, Joanta-Gomez, Adela, Schulte, Jessica, Kreisl, Teri Nguyen, Lassman, Andrew B., Welch, Mary Roberta, Haggiagi, Aya, Iwamoto, Fabio Massaiti

“…Abstract only e13575 Background: Hyperprogressive disease (HPD) has been described in solid tumor patients treated with immune checkpoint inhibitors (ICI). HPD…”
Get full text

Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization by Lee, Eudocia Quant, Trippa, Lorenzo, Fell, Geoffrey, Rahman, Rifaquat, Arrillaga-Romany, Isabel, Touat, Mehdi, Drappatz, Jan, Welch, Mary Roberta, Galanis, Evanthia, Ahluwalia, Manmeet Singh, Colman, Howard, Nabors, Louis B., Hepel, Jaroslaw T., Schiff, David, Meredith, David M., Chiocca, E. Antonio, Reardon, David A., Ligon, Keith L., Alexander, Brian Michael, Wen, Patrick Y.

“…Abstract only 2014 Background: The cyclin D-CDK4/6-Rb pathway is activated in most glioblastomas. Abemaciclib is a potent CDK4/6 inhibitor with good brain…”
Get full text

Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma by Rahman, Rifaquat, Trippa, Lorenzo, Fell, Geoffrey, Lee, Eudocia Quant, Arrillaga-Romany, Isabel, Touat, Mehdi, Drappatz, Jan, Galanis, Evanthia, Ahluwalia, Manmeet Singh, Colman, Howard, Nabors, Louis B., Hepel, Jaroslaw T., Schiff, David, Welch, Mary Roberta, Meredith, David M., Chiocca, E. Antonio, Reardon, David A., Ligon, Keith L., Alexander, Brian Michael, Wen, Patrick Y.

“…Abstract only 2006 Background: Adaptive randomization adjusts enrollment rates based upon early trial results, which can allow for decreased enrollment for…”
Get full text

INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results by Reardon, David A., Brem, Steven, Desai, Arati Suvas, Bagley, Stephen Joseph, Kurz, Sylvia Christine, De La Fuente, Macarena Ines, Nagpal, Seema, Welch, Mary Roberta, Hormigo, Adilia, Carroll, Nicholas, Bartra, Sarah K, Campbell, Patricia, Bhatt, Kamalnayan, Lowy, Israel, Boyer, Jean, Kraynyak, Kimberly, Morrow, Matthew P, McMullan, Trevor, Weiner, David B., Skolnik, Jeffrey

“…Abstract only 2514 Background: Novel T cell-enabling therapies, in combination with checkpoint inhibition, may improve OS in GBM. INO-5401 (synthetic DNA…”
Get full text

LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA by Reardon, David A, Brem, Steven, Desai, Arati Suvas, Bagley, Stephen Joseph, Kurz, Sylvia Christine, De La Fuente, Macarena Ines, Nagpal, Seema, Welch, Mary Roberta, Hormigo, Adilia, Forsyth, Peter, Mandell, Jacob, Khagi, Simon, Aiken, Robert, Walbert, Tobias, Lieberman, Frank, Portnow, Jana, Batiste, James, Carroll, Nicholas, Sylvester, Albert, Campbell, Patricia, Lowy, Israel, Dolgoter, Alex, Boyer, Jean, Kraynyak, Kimberly, Morrow, Matthew P, McMullan, Trevor, Weiner, David B, Skolnik, Jeffrey

“…Abstract BACKGROUND Novel T cell-enabling therapies, in combination with checkpoint inhibition, may improve OS in GBM. INO-5401 (synthetic DNA plasmids…”
Get full text

ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma by Touat, Mehdi, Dubuc, Adrian M., Meredith, David M., Gaffey, Sarah C., Gedulig, Jack E., Ramkissoon, Shakti H., De Groot, John Frederick, Galanis, Evanthia, Welch, Mary Roberta, Nabors, Louis B., Arrillaga, Isabel, Chiocca, E. Antonio, Santagata, Sandro, Schiff, David, Ahluwalia, Manmeet Singh, Colman, Howard, Drappatz, Jan, Alexander, Brian M., Wen, Patrick Y., Ligon, Keith L.

“…Abstract only…”
Get full text

Individualized screening trial of innovative glioblastoma therapy (INSIGhT) by Alexander, Brian Michael, Trippa, Lorenzo, Gaffey, Sarah C., Arrillaga, Isabel, Lee, Eudocia Quant, Tanguturi, Shyam Kumar, Ahluwalia, Manmeet Singh, Colman, Howard, Galanis, Evanthia, De Groot, John Frederick, Drappatz, Jan, Lassman, Andrew B., Nabors, Louis B., Reardon, David A., Schiff, David, Welch, Mary Roberta, Ligon, Keith L., Wen, Patrick Y.

“…Abstract only TPS2079 Background: Patient with glioblastoma (GBM) with unmethylated MGMT promoters derive limited benefit from temozolomide (TMZ) and have…”
Get full text

High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma by Welch, Mary Roberta, Sauter, Craig Steven, Matasar, Matthew J., Moskowitz, Craig, Omuro, Antonio Marcilio Padula

“…Abstract only 2089 Background: In two reports by Soussain et al, promising efficacy was observed in recurrent primary CNS lymphoma with induction…”
Get full text